Sumitomo Pharma Co Ltd Midterm 2027 Business Plan Briefing Transcript
Hello, everyone. My name is Hiroshi Nomura. Thank you very much for taking time out of your busy schedule, to attend or participate today. We issued several press releases at 1 p.m. In addition to the press release for the midterm business plan 2027, we issued the press releases regarding the earnings forecast for FY 2022 and the related dividend and then the dividend for FY 2023.
In FY 2022, there were two major impairment losses. And due to these impairment losses, we managed to keep core operating profit in the black, but the net profit attributable to owners of the parent company was in the red. For FY 2022, we will pay a reduced year-end dividend of JPY 7 per share instead of the usual JPY 14 per share.
And for FY 2023, we have announced the decision of paying no dividend due to a deficit in core operating profit. I'm sorry for this performance. We will strive to improve our business performance by firmly implementing our midterm business plan, which I will explain in the following slides.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
